NCT06484920View on ClinicalTrials.gov

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

September 30, 2029

Conditions
Relapsed Hodgkin LymphomaRefractory Hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaB-cell Lymphoma
Interventions
DRUG

ATRA

150 mg/m2 ATRA orally for 3 days surrounding each of the first four cycles (day -1, day 0, day +1)

DRUG

Pembrolizumab

200mg Q3W pembrolizumab

Trial Locations (2)

46202

RECRUITING

Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

RECRUITING

Sidney and Lois Eskenazi Hospital, Indianapolis

All Listed Sponsors
lead

Rita Assi

OTHER